BlueCrest Capital Management
BlueCrest Capital Management is a private equity firm based in UK. BlueCrest Capital Management has deployed $30M in robotics investments. Its humanoid robotics portfolio includes Neura Robotics. Focus areas include hedge fund, quant, technology investments.
Portfolio companies (1)
Funding rounds (1)
Round size: $130M
About
BlueCrest Capital Management is a private equity firm based in UK. BlueCrest Capital Management has deployed $30M in robotics investments. Its humanoid robotics portfolio includes Neura Robotics. Focus areas include hedge fund, quant, technology investments.
Related news
Moove raises $250M to build infrastructure for autonomous vehicles
Moove raised $250 million in Series C funding, bringing its valuation to $2.1 billion, to build infrastructure for autonomous vehicles including fleet ownership and robotics-first depot facilities called Nests. The company plans to expand globally, grow its autonomous vehicle workforce by over 220%, and through its partnership with Waymo, operates autonomous fleets in Phoenix, Miami, and London.
Neura Robotics and Amazon Web Services enter strategic collaboration to accelerate physical AI at scale
Neura Robotics has entered a strategic collaboration with Amazon Web Services (AWS) to accelerate physical AI at scale. The partnership leverages Neura's cognitive robotics platform combined with AWS's cloud and AI infrastructure to help train, validate, and deploy robots capable of working alongside humans. This collaboration aims to move cognitive robots from development into global deployment.
Tesla eyes Shanghai Gigafactory for Optimus humanoid robot mass production
Tesla is eyeing its Shanghai Gigafactory for mass production of its Optimus Gen 3 humanoid robot, with the facility positioned as a strategic manufacturing hub. Wang Hao, Tesla's president in China, made the comments signaling production planning is further along than public demonstrations have indicated. The company has deployed over 1,000 Optimus units internally and aims to scale production from hundreds to tens of thousands annually by 2027-2028, with a target price below $20,000 per unit. The move puts Tesla directly in competition with Chinese robotics companies including Unitree and Agibot, which already have commercial humanoid robots available at competitive price points. China controls an estimated 90% of the global humanoid robot market, and manufacturing Optimus in Shanghai would give Tesla access to the supply chain, talent pool, and government incentives accelerating Chinese robotics development.